{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-133668","form_type":"8-K","ticker":null,"cik":"0001888012","company_name":"HilleVax, Inc.","filed_at":"2024-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.254760+00:00","generated_at":"2026-05-29T07:26:34.599605+00:00","sec_items":["2.05","5.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"HilleVax cuts 70% of workforce (28 employees) and three officers depart; expects $6.1M severance charges","bullets":["Workforce reduction of 28 employees (approx. 70% of workforce) effective Dec 4, 2024; substantially complete by end of Jan 2025.","Estimated charges of ~$6.1M for severance, benefits, and termination costs; majority recognized in Q4 2024.","COO Sean McLoughlin, CMO Astrid Borkowski, and CBO Aditya Kohli cease officer roles Dec 19; McLoughlin and Kohli become consultants, Borkowski non-executive employee.","Company to continue evaluating norovirus vaccine candidates and exploring business development and strategic alternatives."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-133668","json":"https://secwatch.observer/filing/0000950170-24-133668.json","markdown":"https://secwatch.observer/filing/0000950170-24-133668.md","text":"https://secwatch.observer/filing/0000950170-24-133668.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888012/000095017024133668/0000950170-24-133668-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888012/000095017024133668/hlvx-20241204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T07:26:34.599605+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f805ed1161c10025ce4ad95c011e10f62420e62","claim":"HilleVax, Inc. announced a restructuring with charges of approximately $6.1 million primarily related to employee severance payments, benefits and related termination costs (28 employees, constituting approximately 70% of the Company’s workforce).","evidence_excerpt":"to be substantially complete by the end of January 2025. The Company currently estimates that it will incur charges associated with the workforce reduction of approximately $6.1 million primarily related to employee severance payments, benefits and related termination costs. The Company expects the majority of related charges to be recognized in the fourth","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1888012/000095017024133668/0000950170-24-133668-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $6.1 million primarily related to employee severance payments, benefits and related termination costs"},{"label":"Headcount","value":"28 employees, constituting approximately 70% of the Company’s workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}